NDAINJECTIONINJECTABLE
Approved
May 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
DUOCAINE (bupivacaine hydrochloride; lidocaine hydrochloride) by R-Pharm US is impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Approved for regional anesthesia, analgesia for surgery, dental and 4 more indications. First approved in 2003.
Drug data last refreshed 14h ago · AI intelligence enriched 17h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUOCAINE is a fixed-dose combination injectable local anesthetic containing bupivacaine hydrochloride and lidocaine hydrochloride. It blocks nerve impulses by increasing electrical excitation threshold and slowing nerve impulse propagation, used for regional anesthesia, analgesia, and pain relief across surgical, dental, diagnostic, and obstetrical procedures. The dual-agent formulation extends anesthetic duration and provides rapid onset of action.
LOE Approaching
As an older NDA approved in 2003 with LOE approaching, DUOCAINE faces significant revenue pressure from established competitors; career roles likely focused on managed decline and transition planning rather than growth initiatives.
Mechanism of Action
impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction…
Indications (7)
Worked on DUOCAINE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.